BioSpace News Archive

Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced that two new health system partners.

Clarity Pharmaceuticals is pleased to announce that Dr Neal Shore has joined Clarity’s Clinical Advisory Board.

The Foundation for Sickle Cell Disease Research (FSCDR), the US’s first outpatient center exclusively dedicated to the treatment of and innovative research for SCD, today announced the 16th Annual Sickle Cell Disease Research and Educational Symposium, and the 45th Annual Sickle Cell Disease Scientific Meeting.

VeriSIM Life (VeriSIM) www.verisimlife.com, the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced that it has entered into a partnership agreement with Total Brain www.totalbrain.com.

Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that 100 years of clinical evidence supporting the use of proenzymes as a new therapeutic approach to treat cancer can be considered ‘compelling’.

CorePath is excited to announce a partnership with Cizzle Biotechnology, a UK based diagnostics developer, to develop and offer a proprietary early-stage lung cancer test throughout the United States.

Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it has received final approval from the U.S. Food and Drug Administration for Omeprazole Magnesium Delayed-Release Mini Capsules, 20 mg over-the-counter (OTC).

According to Vision Research Reports, the U.S. office-based labs market size was estimated at around USD 9.7 billion in 2021 and it is projected to hit around USD 18.5 billion by 2030, growing at a CAGR of 7.44% from 2022 to 2030.

According to Vision Research Reports, the Europe mobility aids market was valued at USD 2.9 billion in 2021 and it is predicted to surpass around USD 3.99 billion by 2030 with a CAGR of 3.61% from 2022 to 2030.

Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF,FSE: CWY0) (“Clearmind” or the “Company”), has completed a highly constructive Pre-Investigational New Drug Application (“pre-IND”) meeting with the U.S. Food and Drug Administration (“FDA”) to discuss the development of the Company’s MEAI- based proprietary compound CMND-100.